Bionano Genomics, Inc.

NasdaqCM BNGO

Bionano Genomics, Inc. Market Capitalization on February 06, 2025: USD 13.33 M

Bionano Genomics, Inc. Market Capitalization is USD 13.33 M on February 06, 2025, a 2,857.60% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Bionano Genomics, Inc. 52-week high Market Capitalization is USD 18.50 M on January 23, 2025, which is 38.81% above the current Market Capitalization.
  • Bionano Genomics, Inc. 52-week low Market Capitalization is USD 419.71 K on January 21, 2025, which is -96.85% below the current Market Capitalization.
  • Bionano Genomics, Inc. average Market Capitalization for the last 52 weeks is USD 10.68 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
SV Wall Street
NasdaqCM: BNGO

Bionano Genomics, Inc.

CEO Dr. Robert Erik Holmlin M.B.A., Ph.D.
IPO Date Aug. 21, 2018
Location United States
Headquarters 9540 Towne Centre Drive
Employees 344
Sector Healthcare
Industries
Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Similar companies

NVST

Envista Holdings Corp

USD 21.79

5.93%

STXS

Stereotaxis, Inc.

USD 2.44

-4.69%

MBOT

Microbot Medical Inc.

USD 2.17

6.37%

WST

West Pharmaceutical Services, Inc.

USD 330.47

-1.39%

RMD

ResMed Inc.

USD 237.18

-2.23%

BDX

Becton, Dickinson and Company

USD 227.21

-7.28%

STAA

STAAR Surgical Company

USD 22.83

-3.39%

LUCY

Innovative Eyewear, Inc.

USD 4.74

-9.02%

POAI

Predictive Oncology Inc.

USD 1.53

1.32%

NXGL

NEXGEL, Inc.

USD 3.39

-3.42%

ISRG

Intuitive Surgical, Inc.

USD 588.50

-0.41%

StockViz Staff

February 7, 2025

Any question? Send us an email